Testing GZ17-6.02 for advanced prostate cancer after hormone therapy
Part of Cancer clinical trials.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced prostate cancer that has been treated with hormone therapy (ADT) and at least one other hormone blocking drug (like abiraterone or enzalutamide) and the cancer has progressed.
- Your testosterone level must be very low (equal to or less than 50 ng/dL), which is the typical result of ongoing hormone therapy.
- Your PSA (a marker for prostate cancer) must have risen on two tests taken at least 1 week apart.
- You must have tumors that can be seen on a CT scan or bone scan.
- You must be able to take care of yourself (ECOG performance status 0, 1, or 2).
- You cannot have certain other cancer treatments or take specific medications that interact with the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (ZEN-3694 and enzalutamide) for men with advanced prostate cancer that has stopped responding to standard hormonal treatments. It aims to see if this combination can help slow or stop the cancer from growing.
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests an experimental new drug (GSK5471713) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It is for people who have already tried certain hormone treatments and chemotherapy.
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
This early-phase trial tests a new oral drug, GT-220F, for men whose prostate cancer has spread and no longer responds to hormone therapy. It may be especially for patients whose cancer has specific genetic changes in the PTEN or PIK3CB genes.
Hear when a new Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.